Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Virulence
|
April 2, 2026
Emergence of <i>tmexCD1-toprJ1</i> in the clinical high-risk clone sequence type 147 among carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in China: A multicentre retrospective study
Chengzhen Wang, Siquan Shen, Xun Gao, et al.
Targeted Oncology
|
February 5, 2021
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Ying Cheng, Yong He, Wei Li, et al.
Nature Communications
|
March 20, 2021
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
Tereza Vaclova, Ursula Grazini, Lewis Ward, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 1, 2025
EGFR mutation testing across the osimertinib clinical program
Marie Laure Murat-Onana, Suresh S Ramalingam, Pasi A Jänne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Edurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 5, 2026
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort
Xiaorong Dong, Hong Jian, Meijuan Huang, et al.
The Journal of Molecular Diagnostics : JMD
|
November 19, 2023
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic
Jhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 31, 2019
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, et al.
JTO Clinical and Research Reports
|
February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
Jie Wang, Yi-Long Wu, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 8, 2025
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study
Marina Chiara Garassino, Yong He, Myung-Ju Ahn, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Virulence
|
April 2, 2026
Emergence of <i>tmexCD1-toprJ1</i> in the clinical high-risk clone sequence type 147 among carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in China: A multicentre retrospective study
Chengzhen Wang, Siquan Shen, Xun Gao, et al.
Targeted Oncology
|
February 5, 2021
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Ying Cheng, Yong He, Wei Li, et al.
Nature Communications
|
March 20, 2021
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
Tereza Vaclova, Ursula Grazini, Lewis Ward, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 1, 2025
EGFR mutation testing across the osimertinib clinical program
Marie Laure Murat-Onana, Suresh S Ramalingam, Pasi A Jänne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Edurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 5, 2026
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort
Xiaorong Dong, Hong Jian, Meijuan Huang, et al.
The Journal of Molecular Diagnostics : JMD
|
November 19, 2023
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic
Jhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 31, 2019
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, et al.
JTO Clinical and Research Reports
|
February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
Jie Wang, Yi-Long Wu, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 8, 2025
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study
Marina Chiara Garassino, Yong He, Myung-Ju Ahn, et al.
Page
of 6